Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Almac, Lilly UK to Personalize Lung Cancer Treatment with Alimta/Cisplatin Regimen
September 16, 2009
The two companies announced plans to develop a companion diagnostic to predict whether non-squamous non-small cell lung cancer patients can benefit from combination treatment with Alimta and cisplatin based on the thymidylate synthase biomarker.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Lab21 Offering Companion Testing to Personalize ALK Inhibitors for NSCLC Patients
February 22, 2012 / Pharmacogenomics Reporter - FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
February 1, 2012 / Pharmacogenomics Reporter - Ventana to Develop Companion Dx for Pfizer NSCLC Drug
January 10, 2012 / GenomeWeb Daily News - Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter